TLSA Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Tiziana Life Sciences's net margin of --. Tiziana Life Sciences's return on equity of -- beat CEL-SCI's return on equity of --.

Tiziana Life Sciences has a consensus price target of --, signalling upside risk potential of 307.61%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 2010.63%. Given that CEL-SCI has higher upside potential than Tiziana Life Sciences, analysts believe CEL-SCI is more attractive than Tiziana Life Sciences.

Tiziana Life Sciences has a beta of 0.513, which suggesting that the stock is 48.708% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Tiziana Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Tiziana Life Sciences quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tiziana Life Sciences's net income of -- is lower than CEL-SCI's net income of -$6.9M. Notably, Tiziana Life Sciences's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences is 1,033.93x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Altamira Therapeutics has a net margin of -- compared to Tiziana Life Sciences's net margin of --. Tiziana Life Sciences's return on equity of -- beat Altamira Therapeutics's return on equity of --.

Tiziana Life Sciences has a consensus price target of --, signalling upside risk potential of 307.61%. On the other hand Altamira Therapeutics has an analysts' consensus of -- which suggests that it could grow by 3207.98%. Given that Altamira Therapeutics has higher upside potential than Tiziana Life Sciences, analysts believe Altamira Therapeutics is more attractive than Tiziana Life Sciences.

Tiziana Life Sciences has a beta of 0.513, which suggesting that the stock is 48.708% less volatile than S&P 500. In comparison Altamira Therapeutics has a beta of 2.545, suggesting its more volatile than the S&P 500 by 154.46%.

Tiziana Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altamira Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences pays -- of its earnings as a dividend. Altamira Therapeutics pays out -- of its earnings as a dividend.

Tiziana Life Sciences quarterly revenues are --, which are smaller than Altamira Therapeutics quarterly revenues of --. Tiziana Life Sciences's net income of -- is lower than Altamira Therapeutics's net income of --. Notably, Tiziana Life Sciences's price-to-earnings ratio is -- while Altamira Therapeutics's PE ratio is 0.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences is 1,033.93x versus -- for Altamira Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Kiniksa Pharmaceuticals International PLC has a net margin of -- compared to Tiziana Life Sciences's net margin of -11.31%. Tiziana Life Sciences's return on equity of -- beat Kiniksa Pharmaceuticals International PLC's return on equity of -2.11%.

Tiziana Life Sciences has a consensus price target of --, signalling upside risk potential of 307.61%. On the other hand Kiniksa Pharmaceuticals International PLC has an analysts' consensus of $36.00 which suggests that it could grow by 77.34%. Given that Tiziana Life Sciences has higher upside potential than Kiniksa Pharmaceuticals International PLC, analysts believe Tiziana Life Sciences is more attractive than Kiniksa Pharmaceuticals International PLC.

Tiziana Life Sciences has a beta of 0.513, which suggesting that the stock is 48.708% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International PLC has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.685%.

Tiziana Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International PLC pays out -- of its earnings as a dividend.

Tiziana Life Sciences quarterly revenues are --, which are smaller than Kiniksa Pharmaceuticals International PLC quarterly revenues of $112.2M. Tiziana Life Sciences's net income of -- is lower than Kiniksa Pharmaceuticals International PLC's net income of -$12.7M. Notably, Tiziana Life Sciences's price-to-earnings ratio is -- while Kiniksa Pharmaceuticals International PLC's PE ratio is 176.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences is 1,033.93x versus 3.85x for Kiniksa Pharmaceuticals International PLC. Usually stocks with elevated PS ratios are considered overvalued.

Quantum-Si has a net margin of -- compared to Tiziana Life Sciences's net margin of -3216.39%. Tiziana Life Sciences's return on equity of -- beat Quantum-Si's return on equity of -35.65%.

Tiziana Life Sciences has a consensus price target of --, signalling upside risk potential of 307.61%. On the other hand Quantum-Si has an analysts' consensus of -- which suggests that it could grow by 23.11%. Given that Tiziana Life Sciences has higher upside potential than Quantum-Si, analysts believe Tiziana Life Sciences is more attractive than Quantum-Si.

Tiziana Life Sciences has a beta of 0.513, which suggesting that the stock is 48.708% less volatile than S&P 500. In comparison Quantum-Si has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tiziana Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences pays -- of its earnings as a dividend. Quantum-Si pays out -- of its earnings as a dividend.

Tiziana Life Sciences quarterly revenues are --, which are smaller than Quantum-Si quarterly revenues of $787K. Tiziana Life Sciences's net income of -- is lower than Quantum-Si's net income of -$25.3M. Notably, Tiziana Life Sciences's price-to-earnings ratio is -- while Quantum-Si's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences is 1,033.93x versus 165.39x for Quantum-Si. Usually stocks with elevated PS ratios are considered overvalued.